Definium Therapeutics (DFTX) Non-Current Debt (2023 - 2026)

Definium Therapeutics (DFTX) has 4 years of Non-Current Debt data on file, last reported at $40.8 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $40.8 million, up 85.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.8 million (up 85.03% YoY), and the FY2025 annual result was $40.6 million, up 85.68% from the prior year.
• Non-Current Debt steadied at $40.8 million in Q1 2026 per DFTX's latest filing, from $40.6 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $41.2 million in Q2 2025 and troughed at $14.1 million in Q3 2023.
• A 4-year average of $27.1 million and a median of $24.3 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt jumped 54.67% in 2024, then soared 85.68% in 2025.
• A 4-year view of Non-Current Debt shows it stood at $14.1 million in 2023, then jumped by 54.67% to $21.9 million in 2024, then soared by 85.68% to $40.6 million in 2025, then increased by 0.48% to $40.8 million in 2026.
• Business Quant data shows DFTX's Non-Current Debt at $40.8 million in Q1 2026, $40.6 million in Q4 2025, and $40.4 million in Q3 2025.